Physician profile
Laura K Melaro
NPI 1750450649
$682,175.42
in general payments reported to CMS, 2019-2025
15 companies · $182K in 2025
The $182K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34K · 2022: $123K · 2023: $177K · 2024: $165K · 2025: $182K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $298K · Consulting Fee: $116K · Travel and Lodging: $72K · Honoraria: $21K · Food and Beverage: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $975 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $297,540.19 |
| Consulting Fee | $116,419.25 |
| Travel and Lodging | $71,977.70 |
| Honoraria | $21,004.00 |
| Food and Beverage | $17,104.81 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $975.00 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $364,227.67 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $190,101.09 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83,787.82 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $27,805.34 | 2024-2025 | Auvelity |
| Biogen, INC. | $5,602.36 | 2022-2024 | Zurzuvae |
| Alkermes, INC. | $5,389.26 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Lundbeck LLC | $3,679.77 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| H. Lundbeck A S | $1,088.00 | 2024 | Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $257.22 | 2024-2025 | Cobenfy |
| Sage Therapeutics, LLC | $109.09 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.23 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.00 | 2025 | Uzedy |
| Supernus Pharmaceuticals, INC. | $22.10 | 2021 | |
| Abbvie INC. | $20.01 | 2022 | |
| Nevro Corp. | $17.46 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Melaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.